Table 1

 Baseline characteristics of asthmatic smokers and non-smokers by randomisation dose

Smokers (n = 40)Non-smokers (n = 55)
400 μg2000 μgTotal400 μg2000 μgTotal
Values are mean (SD) unless otherwise stated.
*p<0.05, †p<0.001 (differences between smoking and non-smoking groups only).
Age (years)44 (8)48 (17)46 (13)42 (11)43 (16)43 (14)
Sex (M/F)8/116/1514/2612/1617/1029/26
Taking inhaled corticosteroid at baseline, n (%)7 (37%)9 (43%)16 (40%)*18 (64%)16 (59%)34 (62%)
Median (IQR) μg/day equivalent to beclomethasone0 (0–200)0 (0–400)0 (0–300)200 (0–400)200 (0–400)200 (0–400)
Median (IQR) duration of asthma (years)8 (4–16)12 (6–27)9 (5–21)*19 (8–26)18 (10–27)18 (10–27)
Pack years smoked28 (19)23 (10)25 (15)*0 (0)3 (2)3 (2)
Median (IQR) serum cotinine (ng/ml)285(180–351)298 (134–325)287(164–344)†1 (1–2)2 (1–2)2 (1–2)
Atopic (specific IgE positive), n (%)8 (42%)10 (53%)18 (47%)†20 (71%)24 (92%)44 (81%)
Median (IQR) total IgE (IU/ml)149 (32–567)40 (24–269)54 (30–372)96 (32–238)148 (72–208)117 (49–213)
Reliever inhaler (puffs/day)4 (3)4 (2)4 (3)2 (2)2 (1)2 (2)
FEV1 % predicted pre-salbutamol87 (11)85 (14)86 (13)86 (17)84 (16)85 (16)
FEV1 % predicted post-salbutamol91 (11)91 (15)91 (13)95 (17)95 (15)95 (16)
FEV1/FVC post-salbutamol (%)75 (7)73 (9)74 (8)76 (7)72 (9)74 (8)
Improvement in FEV1 after salbutamol (ml)130 (170)170 (150)150 (160)†300 (200)380 (200)340 (200)
PEF morning (l/min)403 (93)374 (86)388 (90)*427 (77)466 (108)446 (94)
PEF night (l/min)422 (101)409 (102)415 (101)*440 (82)484 (107)461 (97)
Asthma control score1.7 (0.96)2.1 (0.63)1.9 (0.82)†1.1 (0.78)1 (0.73)1.1 (0.75)